On April 2, 2025, Lupin Healthcare (UK) Limited, a wholly owned subsidiary of Lupin Limited, announced the acquisition of the entire share capital of Renascience Pharma Limited (RPL), a UK-based pharmaceutical company, for a cash consideration of GBP 12.3 million.
Strategic Expansion in the UK Market
This acquisition is a strategic move by Lupin to enhance its specialty pharmaceutical portfolio in the United Kingdom. RPL is recognized for its niche bio-generic products supplied to both primary and secondary care markets in the UK.
Financial Performance of Renascience Pharma Limited
As of February 29, 2025, RPL reported a turnover of GBP 3.51 million and a net worth of GBP 0.95 million.
Implications of the Acquisition
By acquiring RPL, Lupin aims to strengthen its position in the UK pharmaceutical market, leveraging RPL’s established product portfolio and market presence. This move aligns with Lupin’s broader strategy to expand its footprint in the global specialty pharmaceutical sector.
The acquisition was completed simultaneously with the execution of the definitive agreement on April 2, 2025, and did not require any regulatory or governmental approvals.
This development underscores Lupin’s commitment to enhancing its global presence and diversifying its product offerings to meet the evolving needs of patients and healthcare providers.
